Mechanistically , ADSCs mitigate insulin resistance in T2DM by suppressing chronic inflammation via polarization of pro-inflammatory M1 macrophages to anti-inflammatory M2 phenotypes, a process mediated by interleukin-10 (IL-10) and inhibition of NLRP3 inflammasome activation (17, 18) . The gene discussed is IL10; the disease is Insulin resistance.